Aspen Investment Management Inc acquired a new position in Moderna, Inc. (NASDAQ:MRNA – Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,390 shares of the company’s stock, valued at approximately $579,000.
Other institutional investors have also added to or reduced their stakes in the company. Lingotto Investment Management LLP increased its holdings in Moderna by 33.7% in the fourth quarter. Lingotto Investment Management LLP now owns 498,693 shares of the company’s stock worth $14,706,000 after purchasing an additional 125,598 shares in the last quarter. Douglas Lane & Associates LLC boosted its holdings in shares of Moderna by 14.4% during the 4th quarter. Douglas Lane & Associates LLC now owns 1,291,465 shares of the company’s stock worth $38,085,000 after buying an additional 163,031 shares in the last quarter. Nicollet Investment Management Inc. bought a new position in shares of Moderna during the 4th quarter worth approximately $897,000. Banco Santander S.A. grew its position in shares of Moderna by 22.1% during the 3rd quarter. Banco Santander S.A. now owns 215,894 shares of the company’s stock worth $5,577,000 after buying an additional 39,056 shares during the period. Finally, Sigma Planning Corp acquired a new stake in shares of Moderna during the 4th quarter worth approximately $907,000. 75.33% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a report on Thursday. Royal Bank Of Canada lifted their price target on shares of Moderna from $35.00 to $38.00 and gave the company a “sector perform” rating in a research note on Monday, May 4th. The Goldman Sachs Group upped their price objective on shares of Moderna from $43.00 to $49.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Finally, Bank of America increased their price objective on shares of Moderna from $32.00 to $34.00 and gave the stock an “underperform” rating in a research report on Monday, June 8th. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $36.60.
Moderna Stock Performance
Shares of MRNA stock opened at $63.96 on Friday. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The firm has a fifty day simple moving average of $50.56 and a two-hundred day simple moving average of $45.23. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $67.74. The firm has a market capitalization of $25.38 billion, a PE ratio of -7.85 and a beta of 1.05.
Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The business had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm’s quarterly revenue was up 260.2% on a year-over-year basis. During the same period last year, the business posted ($2.52) earnings per share. Analysts forecast that Moderna, Inc. will post -6.51 EPS for the current fiscal year.
Insider Buying and Selling at Moderna
In related news, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider owned 67,468 shares in the company, valued at $3,373,400. This represents a 4.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 125,088 shares of company stock worth $6,193,713. 10.80% of the stock is currently owned by insiders.
Key Moderna News
Here are the key news stories impacting Moderna this week:
- Positive Sentiment: FDA advisers unanimously backed Moderna’s mRNA flu vaccine, boosting confidence that the shot could win approval and become a new revenue driver if the agency follows the panel’s recommendation. Article: MRNA Up as Influenza Vaccine Wins Unanimous FDA Advisory Panel Backing
- Positive Sentiment: Investor sentiment was also helped by reports that Moderna’s shares have been surging on the flu-vaccine catalyst, with some traders positioning for further upside ahead of the FDA’s final ruling. Article: US FDA advisers vote in favor of Moderna’s flu vaccine
- Positive Sentiment: Unusually heavy call-option buying signals that some investors are betting the rally can continue as the FDA review progresses. Article: Moderna, Inc. (NASDAQ:MRNA) – Get Free Report
- Neutral Sentiment: Moderna’s president sold shares under a pre-arranged trading plan, which is worth noting but does not necessarily indicate a change in the company’s outlook. Article: Moderna (NASDAQ:MRNA) President Sells $2,739,870.32 in Stock
- Neutral Sentiment: The stock may stay volatile until the FDA makes its final decision on the flu vaccine by Aug. 5. Article: Moderna’s mRNA flu vaccine faces FDA advisory panel scrutiny
About Moderna
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Recommended Stories
- Five stocks we like better than Moderna
- 3 Retail Winners Using Cash Flow to Stay Ahead
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
